ArthroCare’s platform technology is indicated for soft tissue debridement in arthroscopic and orthopedic applications, which includes treating diabetic foot ulcers among other soft tissue conditions.
ArthroCare is evaluating pathways to expand product indications to include diabetic foot ulcers as a specific treatment methodology and will work with FDA for specific product labeling. With hospitalization and amputation often being the only options for patients, ArthroCare’s Sports Medicine division is working with surgeons to develop less invasive, more effective alternatives.
Jack Giroux, president of ArthroCare Sports Medicine, said: “We’re constantly exploring new applications for our technology that can help surgeons achieve superior outcomes and we think we may have something very special here that could potentially provide a large patient population with relief.”